About IVERIC bio
IVERIC bio is a company based in New York (United States) founded in 2007 was acquired by Astellas Pharma in April 2023.. IVERIC bio has raised $206.77 million across 10 funding rounds from investors including Blackstone, Astellas Pharma and Novo Holdings. The company has 94 employees as of December 31, 2021. IVERIC bio operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter New York, United States
- Employees 94 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$206.77 M (USD)
in 10 rounds
-
Latest Funding Round
$11.4 M (USD), Private Equity Round
Oct 30, 2018
-
Investors
Blackstone
& 3 more
-
Employee Count
94
as on Dec 31, 2021
-
Acquired by
Astellas Pharma
(Apr 29, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of IVERIC bio
IVERIC bio has successfully raised a total of $206.77M across 10 strategic funding rounds. The most recent funding activity was a Private Equity Round round of $11.4 million completed in October 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Private Equity Round — $11.4M
-
First Round
First Round
(13 Aug 2007)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2018 | Amount | Private Equity Round - IVERIC bio | Valuation |
investors |
|
| Jan, 2014 | Amount | Private Equity Round - IVERIC bio | Valuation |
investors |
|
| Jun, 2013 | Amount | Series C - IVERIC bio | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in IVERIC bio
IVERIC bio has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Blackstone, Astellas Pharma and Novo Holdings. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Founded Year | Domain | Location | |
|
Venture capital fund focused on early-stage healthcare startups
|
Founded Year | Domain | Location | |
|
Diversified investment management is provided across multiple asset classes.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by IVERIC bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - IVERIC bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Iveric Bio Comparisons
Competitors of IVERIC bio
IVERIC bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Iveric Bio
Frequently Asked Questions about IVERIC bio
When was IVERIC bio founded?
IVERIC bio was founded in 2007.
Where is IVERIC bio located?
IVERIC bio is headquartered in New York, United States. It is registered at New York, New York, United States.
Is IVERIC bio a funded company?
IVERIC bio is a funded company, having raised a total of $206.77M across 10 funding rounds to date. The company's 1st funding round was a Series C of $16.67M, raised on Aug 13, 2007.
How many employees does IVERIC bio have?
As of Dec 31, 2021, the latest employee count at IVERIC bio is 94.
What does IVERIC bio do?
IVERIC bio was founded in 2007 in New York, United States, within the biotechnology sector. Focus is placed on gene therapies targeting retinal conditions. Operations involve advancing candidates such as Zimura, which addresses age-related macular degeneration, and IC-100, a mutation-independent therapy using an AAV5 vector. This approach reduces toxic rhodopsin from mutated genes while introducing healthy protein via a single delivery system.
Who are the top competitors of IVERIC bio?
IVERIC bio's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Who are IVERIC bio's investors?
IVERIC bio has 4 investors. Key investors include Blackstone, Astellas Pharma, Novo Holdings, and SV Health Investors.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.